Fraction of incident diabetes cases attributable to SARS-CoV-2 infection was 3.41 percent overall, 4.75 percent among men
Risk for Diabetes After COVID-19 Still Increased During Omicron Phase
Risk for new-onset diabetes significantly elevated during omicron-dominant phase, but no increase seen for risks for hypertension, hyperlipidemia
SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients
SGLT-2is associated with lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists, metformin
Risks for Diabetes, CVD Up in Acute, Postacute COVID-19 Phases
However, from 13 to 52 weeks after COVID-19, no increase was seen for diabetes mellitus, cardiovascular disease
ADA: Diabetes May Quadruple Risk for Long COVID
Authors say review findings are limited by heterogenous definitions of long COVID in published studies
Risk, Burden of Diabetes Up After Acute SARS-CoV-2 Infection
Risks and burdens of postacute outcomes increased in graded manner based on COVID-19 severity
Newly Diagnosed Diabetes at COVID-19 Admission Profiled
Lower levels of glucose and HbA1c, higher levels of inflammatory markers seen in COVID-19 patients with NDDM versus preexisting diabetes
Risk for Diabetes Increased for Pediatric Patients With COVID-19
Increased incidence of diabetes seen among patients aged younger than 18 years after acute COVID-19 infection versus those without COVID-19
Access to Care Disrupted for Young Adults With Diabetes in COVID-19
Young adults with diabetes also report lower intention of receiving COVID-19 vaccination compared with those 60 years or older